...
首页> 外文期刊>International Immunology >Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding
【24h】

Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding

机译:人体细胞中TLR9抑制活性的最佳寡核苷酸序列:与TLR9结合缺乏相关性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Toll-like receptor (TLR)9 performs our innate response to bacterial DNA, warning us of the presence of infection. Inhibitory oligodeoxyribonucleotides (INH-ODN) have been developed that selectively block activation of mouse TLR9. Their inhibitory motif consisting of CCx(not-C)(not-C)xxGGG (x = any base) also reduces anti-DNA antibodies in lupus mice. The current study demonstrates that this motif also provides the sequences required to block TLR9 in human B cells and human embryonic kidney (HEK) cells transfected with human TLR9. However, extending the sequence by four to five bases at the 5' end enhanced activity and this enhancement was greater when a phosphorothioate (pS) backbone replaced the native phosphodiester (pO) backbone. A series of pO-backbone INH-ODN representing a 500-fold range of activity in biologic assays was shown to cover less than a 2.5-fold range of avidity for binding human TLR9-Ig fusion protein, eliminating TLR9 ectodomain binding as the explanation for sequence-specific differences in biologic activity. With few exceptions, the relative activity of INH-ODN in Namalwa cells and HEK/human TLR9 cells was similar to that seen in mouse B cells. INH-ODN activity in human peripheral blood B cells correlated significantly with the cell line data. These results favor the conclusion that although the backbone determines strength of TLR9 binding, critical recognition of the INH-ODN sequence necessary for biologic activity is performed by a molecule that is not TLR9. These studies also identify the strongest INH-ODN for human B cells, helping to guide the selection of INH-ODN sequences for therapeutics in any situation where inflammation is enhanced by TLR9.
机译:Toll样受体(TLR)9执行我们对细菌DNA的先天反应,警告我们存在感染。已开发出选择性抑制小鼠TLR9活化的抑制性寡脱氧核糖核苷酸(INH-ODN)。它们的抑制基序由CCx(not-C)(not-C)xxGGG(x =任何碱基)组成,还可以降低狼疮小鼠的抗DNA抗体。当前的研究表明,该基序还提供了在人类B细胞和转染了人类TLR9的人类胚胎肾脏(HEK)细胞中阻断TLR9所需的序列。但是,在5'端将序列延长4至5个碱基可增强活性,当硫代磷酸酯(pS)骨架取代天然磷酸二酯(pO)骨架时,这种增强作用更大。一系列的pO骨干INH-ODN在生物学分析中代表500倍范围的活性,显示其结合人TLR9-Ig融合蛋白的亲和力小于2.5倍范围,消除了TLR9胞外域的结合,从而可以解释生物活性的序列特异性差异。除少数例外,在Namalwa细胞和HEK /人TLR9细胞中INH-ODN的相对活性类似于在小鼠B细胞中观察到的相对活性。人外周血B细胞中的INH-ODN活性与细胞系数据显着相关。这些结果支持这样的结论:尽管主链决定了TLR9结合的强度,但生物学活性所必需的INH-ODN序列的关键识别是由非TLR9的分子完成的。这些研究还确定了人类B细胞最强的INH-ODN,有助于指导在TLR9增强炎症的任何情况下选择INH-ODN序列进行治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号